


## PHARMACEUTICAL 2023

## G1 Therapeutics Inc. Rank 313 of 446







## PHARMACEUTICAL 2023

## G1 Therapeutics Inc. Rank 313 of 446



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of G1 Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -19%, being 62% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	179,500
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,588
Liabilities, Non-Current	5,615
Other Assets	6,476
Other Compr. Net Income	0
Other Expenses	5,448
Other Liabilities	78,015
Other Net Income	-9,681
Other Revenues	51,301
Property and Equipment	1,989
Research and Development	83,316
Selling, General and Administrative Expense	100,415

Output Variable	Value in 1000 USD
Assets	187,965
Liabilities	119,218
Expenses	189,179
Revenues	51,301
Stockholders Equity	68,747
Net Income	-147,559
Comprehensive Net Income	-147,559
Economic Capital Ratio	-19%

